Letting Medicare Negotiate Drug Prices Won’t Fix High Patient Costs: PhRMA Ceo | Barron’s

Lawmakers’ plans to allow Medicare to negotiate drug prices will come as a rude surprise to patients, writes Stephen J. Ubl. GEORGE FREY/AFP/Getty Images About the author: Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America, which represents America’s leading biopharmaceutical research companies. House Democrats this week approved a $3.5 trillion budget framework that has already passed the Senate.

Read the source article at barrons.com
2021-08-25 08:30:00